Skip to content
Medical Health Aged Care

Embedding Genomic Research in Cancer Clinical Trials

Cancer Australia 2 mins read

The Albanese Labor Government is taking a significant step forward in cancer research and care by establishing the Cancer Genomics Clinical Trials Fund to drive advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics.

This initial $3 million investment will be open to Australia's 14 Multi-site Collaborative Cancer Clinical Trials Groups as part of the Support for Cancer Clinical Trials (SCCT) program. This new Fund is a significant first step in implementing the National Framework for Genomics in Cancer Control, addressing key objectives for genomics-informed diagnosis, treatment, clinical trials, research and data.

The Cancer Clinical Trials Groups, which develop investigator-initiated cancer clinical trials independent of industry, focus on areas of unmet need. By funding these groups, the Cancer Genomics Clinical Trials Fund aims to deliver the actions outlined in the Genomics Framework, in line with the SCCT program objectives. It will foster innovation in clinical trial design, using genomics and molecular targeting techniques, accelerating the translation of genomic medicine into clinical practice.

Consultation with the Cancer Clinical Trials Groups is underway to ensure the design of the Fund is robust and aligned with sector needs. This collaborative approach will help maximise the impact of this investment on cancer research and patient outcomes.

It is important that all Australians have equitable access to genomic medicine. This is not the case for many including those from underserved populations.  The Cancer Genomics Clinical Trials Fund is a new opportunity to progress advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics.

Quotes attributable to Mark Butler, Minister for Health and Aged Care

"We are living through a supercharged period of discovery that promises to extend the health and wellbeing of Australians, and the Australian Government is proud to fund this important work."

“The Cancer Genomics Clinical Trials Fund demonstrates our commitment to harnessing the power of genomics to revolutionise cancer care for all Australians. By supporting innovative research and clinical trials, we are paving the way for more personalised and effective cancer treatments, offering new hope to patients across the country.”

Quotes attributable to Professor Dorothy Keefe, CEO Cancer Australia

Genomics is a rapidly advancing field, and by embedding genomics into clinical trials, we can enhance our understanding of cancer and potentially offer new management options for patients. This approach may be particularly valuable when exploring treatments for those who have not responded to existing therapies or are waiting for new treatments to become available.”

“Collaboration with the sector will ensure the Cancer Genomics Clinical Trials Fund's investment in genomic medicine translates into the greatest possible impact and real benefits for patients.”


Media Contact:

[email protected]

0438 209 833

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.